Cargando…

Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)

BACKGROUND: Schizophrenia is a severe and often difficult to treat psychiatric illness. In many patients, negative symptoms dominate the clinical picture. Meta-analysis has suggested moderate, but significant effects of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) on these s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebel, T., Langguth, B., Schecklmann, M., Schoisswohl, S., Staudinger, S., Schiller, A., Ustohal, L., Sverak, T., Horky, M., Kasparek, T., Skront, T., Hyza, M., Poeppl, T.B., Riester, M.L., Schwemmer, L., Zimmermann, S., Sakreida, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804178/
https://www.ncbi.nlm.nih.gov/pubmed/35128142
http://dx.doi.org/10.1016/j.conctc.2022.100891
_version_ 1784643017075851264
author Hebel, T.
Langguth, B.
Schecklmann, M.
Schoisswohl, S.
Staudinger, S.
Schiller, A.
Ustohal, L.
Sverak, T.
Horky, M.
Kasparek, T.
Skront, T.
Hyza, M.
Poeppl, T.B.
Riester, M.L.
Schwemmer, L.
Zimmermann, S.
Sakreida, K.
author_facet Hebel, T.
Langguth, B.
Schecklmann, M.
Schoisswohl, S.
Staudinger, S.
Schiller, A.
Ustohal, L.
Sverak, T.
Horky, M.
Kasparek, T.
Skront, T.
Hyza, M.
Poeppl, T.B.
Riester, M.L.
Schwemmer, L.
Zimmermann, S.
Sakreida, K.
author_sort Hebel, T.
collection PubMed
description BACKGROUND: Schizophrenia is a severe and often difficult to treat psychiatric illness. In many patients, negative symptoms dominate the clinical picture. Meta-analysis has suggested moderate, but significant effects of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) on these symptoms. For treatment of depression a much shorter protocol - intermittent theta burst stimulation (iTBS) - has shown to be non-inferior to conventional high-frequency rTMS. This randomized, sham-controlled, rater-blinded clinical trial assesses the effects of conventional HF-rTMS as well as of iTBS of the left dorsolateral prefrontal cortex in comparison with sham. METHODS: The study will be conducted at two psychiatric university hospitals in Germany and at two in the Czech Republic. Assuming an effect size of 0.64 to be detected with a power of 80%, the calculated sample size is 90 patients. Primary outcome will be the difference in the Scale for the Assessment of Negative Symptoms (SANS) score between each active arm and the sham arm at end of treatment. In addition, the trial investigates effects on depressive symptoms, cognitive performance and cigarette smoking. Recording magnetic resonance imaging (MRI) and electroencephalography (EEG) data will serve to assess whether treatment success can be predicted by neural markers and is related to specific neurobiological changes. DISCUSSION: This is a clinical trial directly comparing 10 Hz-rTMS and iTBS in a sham-controlled manner in treating negative symptoms of schizophrenia. If successful, this would present an interesting treatment option for a chronic and severe condition that can be applied at most psychiatric hospitals and only takes up a few minutes per day. TRIAL REGISTRATION NUMBER: This trial has been registered at clinicaltrials.gov, Identifier: NCT04318977. DATA DISSEMINATION: Results from the trial shall be published in peer-reviewed journals and presented at meetings and conferences.
format Online
Article
Text
id pubmed-8804178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88041782022-02-04 Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN) Hebel, T. Langguth, B. Schecklmann, M. Schoisswohl, S. Staudinger, S. Schiller, A. Ustohal, L. Sverak, T. Horky, M. Kasparek, T. Skront, T. Hyza, M. Poeppl, T.B. Riester, M.L. Schwemmer, L. Zimmermann, S. Sakreida, K. Contemp Clin Trials Commun Article BACKGROUND: Schizophrenia is a severe and often difficult to treat psychiatric illness. In many patients, negative symptoms dominate the clinical picture. Meta-analysis has suggested moderate, but significant effects of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) on these symptoms. For treatment of depression a much shorter protocol - intermittent theta burst stimulation (iTBS) - has shown to be non-inferior to conventional high-frequency rTMS. This randomized, sham-controlled, rater-blinded clinical trial assesses the effects of conventional HF-rTMS as well as of iTBS of the left dorsolateral prefrontal cortex in comparison with sham. METHODS: The study will be conducted at two psychiatric university hospitals in Germany and at two in the Czech Republic. Assuming an effect size of 0.64 to be detected with a power of 80%, the calculated sample size is 90 patients. Primary outcome will be the difference in the Scale for the Assessment of Negative Symptoms (SANS) score between each active arm and the sham arm at end of treatment. In addition, the trial investigates effects on depressive symptoms, cognitive performance and cigarette smoking. Recording magnetic resonance imaging (MRI) and electroencephalography (EEG) data will serve to assess whether treatment success can be predicted by neural markers and is related to specific neurobiological changes. DISCUSSION: This is a clinical trial directly comparing 10 Hz-rTMS and iTBS in a sham-controlled manner in treating negative symptoms of schizophrenia. If successful, this would present an interesting treatment option for a chronic and severe condition that can be applied at most psychiatric hospitals and only takes up a few minutes per day. TRIAL REGISTRATION NUMBER: This trial has been registered at clinicaltrials.gov, Identifier: NCT04318977. DATA DISSEMINATION: Results from the trial shall be published in peer-reviewed journals and presented at meetings and conferences. Elsevier 2022-01-20 /pmc/articles/PMC8804178/ /pubmed/35128142 http://dx.doi.org/10.1016/j.conctc.2022.100891 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Hebel, T.
Langguth, B.
Schecklmann, M.
Schoisswohl, S.
Staudinger, S.
Schiller, A.
Ustohal, L.
Sverak, T.
Horky, M.
Kasparek, T.
Skront, T.
Hyza, M.
Poeppl, T.B.
Riester, M.L.
Schwemmer, L.
Zimmermann, S.
Sakreida, K.
Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title_full Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title_fullStr Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title_full_unstemmed Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title_short Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
title_sort rationale and study design of a trial to assess rtms add-on value for the amelioration of negative symptoms of schizophrenia (radovan)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804178/
https://www.ncbi.nlm.nih.gov/pubmed/35128142
http://dx.doi.org/10.1016/j.conctc.2022.100891
work_keys_str_mv AT hebelt rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT langguthb rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT schecklmannm rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT schoisswohls rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT staudingers rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT schillera rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT ustohall rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT sverakt rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT horkym rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT kasparekt rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT skrontt rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT hyzam rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT poeppltb rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT riesterml rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT schwemmerl rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT zimmermanns rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan
AT sakreidak rationaleandstudydesignofatrialtoassessrtmsaddonvaluefortheameliorationofnegativesymptomsofschizophreniaradovan